At 10.6% CAGR, the Middle East & Africa Aortic Valve Replacement Devices Market is Projected to be Worth US$ 625.23 million by 2030, says The Business Market Insights

According to the Business Market Insights’ research, the Middle East & Africa aortic valve replacement devices market was valued at US$ 279.19 million in 2022 and is expected to reach US$ 625.23 million by 2030, registering a CAGR of 10.6% from 2022 to 2030. Rising number of aortic valve replacement surgeries and increasing demand for minimally invasive techniques are among the critical factors attributed to the Middle East & Africa aortic valve replacement devices market expansion.                     

There has been a significant increase in the number of aortic valve replacement surgeries performed worldwide recently. The mitral or aortic valves are repaired or replaced in almost all of these procedures. This surge can be attributed to several factors, including advancements in medical technology, an aging population, and improved awareness of heart-related conditions. Aortic valve replacement is a critical procedure often used to treat aortic valve stenosis or regurgitation, conditions that can lead to serious complications if left untreated. As medical science continues to evolve, these surgeries are expected to become even safer and more accessible, contributing to better patient outcomes and improved quality of life for those affected by aortic valve diseases. Healthcare systems are adapting to accommodate this growing demand for surgical interventions, emphasizing the importance of preventive measures and early detection in managing cardiovascular health.

On the contrary, product recalls hurdle the growth of Middle East & Africa aortic valve replacement devices market.

Based on product, the Middle East & Africa aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve segment held 62.4% share of Middle East & Africa aortic valve replacement devices market in 2022, amassing US$ 174.28 million. It is projected to garner US$ 403.78 million by 2030 to expand at 11.1% CAGR during 2022–2030.

Based on surgery, the Middle East & Africa aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held 86.1% share of Middle East & Africa aortic valve replacement devices in 2022, amassing US$ 240.25 million. It is projected to garner US$ 556.53 million by 2030 to expand at 11.1% CAGR during 2022–2030.  

Based on end user, the Middle East & Africa aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held 65.1% share of Middle East & Africa aortic valve replacement devices market in 2022, amassing US$ 181.85 million. It is projected to garner US$ 419.94 million by 2030 to expand at 11.0% CAGR during 2022–2030.

Based on country, the Middle East & Africa aortic valve replacement devices market has been categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa.  Our regional analysis states that Saudi Arabia captured 40.5% share of Middle East & Africa aortic valve replacement devices market in 2022. It was assessed at US$ 113.10 million in 2022 and is likely to hit US$ 267.6 million by 2030, exhibiting a CAGR of 11.4% during 2022–2030.      

Key players operating in the Middle East & Africa aortic valve replacement devices market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, and Artivion Inc., among others.   

In May 2023, Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low structural valve deterioration (SVD) rates in bioprosthetic aortic valves with the company's innovative RESILIA tissue. The data, representing the longest clinical follow-up for Edwards' bioprosthetic surgical aortic valve with RESILIA tissue with a mean follow-up of 7.7 years, were presented at the 103rd annual meeting of the American Association for Thoracic Surgery.    

In Feb 2023, Medtronic relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com